| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/20/2023 | 183.02% | Lake Street | → $1.5 | Assumes | → Buy |
| 05/20/2022 | 2164.15% | Lake Street | → $12 | Initiates Coverage On | → Buy |
| 10/14/2020 | 88.68% | Maxim Group | → $1 | Initiates Coverage On | → Buy |
| 06/19/2019 | 277.36% | Benchmark | → $2 | Initiates Coverage On | → Speculative Buy |
What is the target price for Biolase (BIOL)?
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on January 20, 2023. The analyst firm set a price target for $1.50 expecting BIOL to rise to within 12 months (a possible 183.02% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biolase (BIOL)?
The latest analyst rating for Biolase (NASDAQ: BIOL) was provided by Lake Street, and Biolase their buy rating.
When is the next analyst rating going to be posted or updated for Biolase (BIOL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biolase, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biolase was filed on January 20, 2023 so you should expect the next rating to be made available sometime around January 20, 2024.
Is the Analyst Rating Biolase (BIOL) correct?
While ratings are subjective and will change, the latest Biolase (BIOL) rating was a with a price target of $0.00 to $1.50. The current price Biolase (BIOL) is trading at is $0.53, which is within the analyst's predicted range.